MindRank advances AI-designed weight loss drug to Phase 3 trials

Hangzhou-based biotech start-up MindRank has entered Phase 3 clinical trials for its weight loss drug, marking China’s first AI-assisted Category 1 new drug to reach this stage. The trial involves MDR-001, a small-molecule GLP-1 receptor agonist developed using AI-driven techniques.

MindRank said the weight loss drug was designed to regulate blood sugar and appetite by mimicking natural hormones. According to founder and chief executive Niu Zhangming, the company is targeting regulatory approval in the second half of 2028, with a potential market launch in 2029.

The company said the development process for the weight loss drug took about 4.5 years, significantly shorter than the typical 7 to 10 years required to reach Phase 3 trials. Niu attributed the acceleration to AI tools that reduced research timelines and cut overall R&D costs by more than 60 per cent.

China-based MindRank uses proprietary AI systems, including large language models (LLMs), to identify weight-loss drug targets and shortlist compounds. The approach has raised target research accuracy above 97 per cent and supports safety and efficacy assessments.

Despite these advances, Niu said human expertise remains essential for strategic decision-making and integrating workflows. He added that AI-assisted drug discovery still faces long validation cycles, meaning its impact on life sciences may be more gradual than in other sectors.

Would you like to learn more about AI, tech, and digital diplomacy? If so, ask our Diplo chatbot!